Lonza and InduPro have signed a licensing agreement to advance next-generation antibody-drug conjugates (ADC) therapies. 

Under the terms of the agreement, Lonza will grant InduPro a non-exclusive, worldwide license to its proprietary GlycoConnect, HydraSpace and linker-payload technologies. These technologies will be applied to the development of ADCs targeting up to two oncology antigens, supporting the advancement of highly targeted cancer therapies. 

InduPro will then combine its proprietary bispecific antibody capabilities with Lonza’s ADC platform, including GlycoConnect, HydraSpace, and SYNtecan E. By leveraging these complementary technologies, the companies aim to develop differentiated therapeutic approaches designed to address complex diseases such as cancer, where precision targeting and efficacy remain critically important. 

“We are pleased to be starting this collaboration with InduPro, which underscores the strength and versatility of our ADC platform,” said Jan Vertommen, Vice President of Commercial Development, Advanced Synthesis at Lonza. 

“By combining our expertise in bioconjugation technologies and manufacturing with InduPro’s innovative proximity guided antibody platform, we reinforce our commitment to enabling our licensing partners and supporting the advancement of next-generation ADC programmes.” 

“This agreement represents an important step in advancing our pipeline of proximity-driven bispecific ADCs,” added Prakash Raman, CEO of InduPro. 

“By combining InduPro’s ability to identify novel, disease-specific co-target pairs with Lonza’s industry-leading ADC technologies, we aim to develop differentiated, first-in-class therapeutics that improve selectivity, expand therapeutic windows, and ultimately deliver better outcomes for patients with hard-to-treat tumours.” 

The post Lonza and InduPro to collaborate on next-gen ADC therapies  appeared first on Drug Discovery World (DDW).